Unity Biotechnology

American biotechnology company From Wikipedia, the free encyclopedia

Unity Biotechnology, Inc. was a publicly traded American biotechnology company that develops drugs that target senescent cells.[1][2][3][4][5] The company ceased operations in 2025.[6]

Company typePublic
PredecessorForge, Inc.
Quick facts Company type, Traded as ...
Unity Biotechnology, Inc.
Company typePublic
IndustryBiotechnology, Pharmaceutical
PredecessorForge, Inc.
Founded2011; 15 years ago (2011) in California, U.S.
Founders
Headquarters,
United States
Number of employees
70 (2018)
Websiteunitybiotechnology.com
Close

History

Unity BioTechnologies, a company backed by Jeff Bezos and PayPal co-founder Peter Thiel,[7] was co-founded in March 2009 by Nathaniel David, Jan Van Deursen, Judith Campisi, and Daohong Zhou.[8]

The company was founded under the name Forge, Inc., but changed its name to Unity BioTechnologies in January 2015.[9]

Anirvan Ghosh joined Unity in 2020 as the company’s CEO. That same year, Nathaniel stepped down as president but remained a member of the board.[10]

On May 3, 2018, the company went public on the Nasdaq exchange, raising $85 million at a market capitalization of $700 million.[11][12] Unity Biotechnology shares dropped 60% on August 17, 2020, after the company reported disappointing results from a clinical trial involving its then lead drug candidate, UBX0101, in patients with moderate-to-severe painful osteoarthritis.[13]

Products

The company's products in development include UBX1325, which targets Bcl-xL, a mechanism to eliminate senescent cells in age-related eye diseases (in Phase 2 clinical trials for diabetic macular edema as of October 2023).[14] In July 2022, the company reported positive results from its Phase 1 study.[15] In April 2023, the company then reported results from its Phase 2 study demonstrating that a single injection of UBX1325 resulted in a statistically significant and clinically meaningful improvement in vision through 48 weeks.[16] They also include UBX 1967, a preclinical product targeting ophthalmologic diseases.[17][12][18] Both products are senolytic medicines.

See also

References

Related Articles

Wikiwand AI